UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): ~~December~~January 3018, ~~2021~~2022 PREDICTIVE TECHNOLOGY GROUP, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization)

000-56008	90-1139372
(Commission File Number)	(IRS Employer Identification No.)

2735 E. Parleys Way, Suite 205, Salt Lake City, Utah	84109
(principal executive offices)	(Zip Code)

+1 (888) 407-9761

(registrant’s telephone number, including area code)

_____________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share		PRED		OTC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

-Item 1.01 - Entry into a Material Definitive Agreement

~~Item~~Pursuant 1to the binding Term Sheet executed on December 30, 2021, on January 18, 2022, Healthtech Solutions, Inc.01 (“Healthtech”) and its newly-organized ~~Entry~~subsidiary, Healthtech Wound Care, Inc. (“HWC”) entered into an Asset Purchase Agreement (the “AP Agreement”) with Predictive Technology Group, Inc. (“PTG”) and its subsidiary, Predictive Biotech, Inc. (“Biotech”). The AP Agreement provides that, at a ~~Material~~future ~~Definitive~~closing (to occur on or before January 31, 2022), HWC will acquire the assets of Biotech that are related to Biotech’s wound care business and will enter into an Operations Agreement with Biotech and PTG containing terms of their future relationship. At the closing, Healthtech will also receive from PTG three year options to purchase Biotech and/or Cellsure, LLC, another subsidiary of PTG, each for a purchase price of $10. Until January 31, 2025, regardless of any purchase of Biotech by Healthtech, PTG will be entitled to remove from Biotech any assets not related to the wound care business. During the three year term of the options, Healthtech will be entitled to exercise exclusive managerial control over the operations of Cellsure and over the operations of Biotech related to wound care.s (Refer to Exhibit 10.1 attached)

~~>On~~In ~~December~~consideration ~~30,~~of ~~2021, Predictive Technology Group, Inc.(“Predictive”), a corporation incorporated and existing under~~ the ~~laws~~transfer of ~~Nevada~~assets ~~(traded~~to inHWC, ~~the~~PTG ~~OTC~~will ~~Market~~receive ~~under~~preferred ~~the~~shares ~~symbol~~in ~~“PRED”) entered into a binding term sheet (the “Agreement”) with Healthtech Solutions, Inc~~HWC. ~~(“Healthtech”),~~Until aHWC ~~company~~achieves ~~incorporated~~positive ~~under~~cash ~~the~~flow ~~laws~~or ~~of Utah~~$3.5 ~~Under~~million ~~the~~in ~~terms~~capital ~~of the Agreement, Predictive~~ has ~~agreed~~been tocontributed ~~sell~~ to ~~Healthtech~~HWC, ~~its~~the ~~wound~~preferred ~~care~~shares ~~related~~held ~~assets owned primarily~~ by ~~Predictive~~PTG ~~Biotech,~~will ~~Inc.~~represent (a30% ~~wholly owned subsidiary~~ of ~~Predictive).~~HWC’s Inequity ~~consideration~~and ~~for~~voting ~~these~~power. ~~assets,~~The ~~among~~Operations ~~other~~Agreement ~~things, Healthtech~~ will ~~create~~commit aHealthtech ~~company~~ to ~~commercialize the wound care assets, and Predictive will receive a thirty percent (30%) ownership interest in that company. Healthtech will~~ provide ~~operating~~working capital to ~~the~~HWC ~~newly formed company~~ and ~~to Predictive~~ Biotech. Inuntil ~~addition,~~HWC ~~Healthtech~~achieves ~~has~~positive ~~agreed~~cash toflow ~~make~~or ~~loans~~Healthtech tocontributes ~~Predictive in the approximate amount of~~ $~~500,000~~3.5 ~~upon~~million ~~the~~or ~~achievement~~Healthtech ofdetermines ~~certain~~that ~~benchmarks,~~market ~~including~~conditions ~~the~~make ~~mutual~~it ~~execution~~unlikely ofthat aHWC ~~formal purchase agreement for the wound care assets. Under the Agreement Predictive~~ will ~~also~~be ~~receive~~financially ~~an initial 20% royalty on the gross margin earned from the sale of wound care products to specified accounts (Refer to Exhibit 10~~successful.1 ~~attached)~~

~~Certain~~Item statements contained in this current report on Form 8-K are forward-looking statements and are based on future expectations, plans and prospects for Predictive’s business and operations and involve a number of risks9. Predictive’s forward-looking statements in this report are made as of the date hereof and Predictive disclaims any duty to supplement, update or revise such statements on a going forward basis whether as a result of subsequent developments, change or expectations or otherwise01. InFinancial ~~connection~~Statements with the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995, any forward looking statements contained herein, including actual events or results may differ materially from those contained in these forward-looking statements. Important factors that could cause further events or results to vary from those addressed in the forward-looking statements include, without limitation, risks and uncertainties arising from the ability of Predictive to meet loan benchmarks; unanticipated or unfavorable regulatory matters; and other risk factors as discussed in Predictive’s other filings made from time to time with the United States Securities and Exchange Commission.Exhibits

~~Item 9~~a.01 Financial ~~Statements and Exhibits~~statements

aNot applicable. ~~Financial~~ ~~statements~~

~~Not applicable~~d. Exhibits

d. Exhibits

Number		Description
10.1		Asset Purchase Agreement dated January 18, 2021

Number	Description
10.1	Acquisition Agreement

-2-

~~-2-~~ SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 24, 2022	PREDICTIVE TECHNOLOGY GROUP, INC.

	By:	/s/ Bradley Robinson
		Chief Executive Officer

Date: January 6, 2022	PREDICTIVE TECHNOLOGY GROUP, INC.
	By /s/ Bradley Robinson
	Chief Executive Officer

-3-

Filing Compare · PREDICTIVE TECHNOLOGY GROUP, INC.